Tag Archives: vrx

Valeant Goes For Allergan; Analyst Touts Shire Option

Valeant Pharmaceuticals International (VRX) officially launched its hostile bid for Allergan on Wednesday, while one analyst speculated that Allergan might counterattack with a tax-inversion acquisition of its own. Valeant took directly to shareholders the sweetened bid for Allergan it unveiled on May 30, amounting to $72 a share in cash plus 0.83 Valeant share per Allergan share. Allergan (AGN) directors rejected that offer, like all of Valeant’s

Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry

With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm — or face, in the case of Botox maker Allergan (AGN). But not all offers have been made peacefully. Valeant Pharmaceuticals (VRX) officially announced plans Tuesday to make its $53 billion bid for Allergan a hostile one. Allergan is one of the three pharmaceutical companies on the Big

Valeant Hikes Bid For Allergan Again; Stocks Rise

Valeant Pharmaceuticals International (VRX) raised its bid for fellow specialty drugmaker Allergan (AGN) again on Friday, but made its offer contingent on “good faith negotiations,” in contrast to its previous hostile bids. Allergan’s stock trading was halted mid-afternoon as Valeant rolled out its latest proposal, which lifted the cash-per-share offer to $72 from $58.30, while retaining Valeant’s stock offering of 0.83 share for each Allergan